Design and fast synthesis of C-terminal duplicated potent C2-symmetric P1/P1′-modified HIV-1 protease inhibitors

被引:76
作者
Alterman, M
Andersson, HO
Garg, N
Ahlsén, G
Lövgren, S
Classon, B
Danielson, UH
Kvarnström, I
Vrang, L
Unge, T
Samuelsson, B
Hallberg, A
机构
[1] Uppsala Univ, Dept Organ Pharmaceut Chem, BMC, SE-75123 Uppsala, Sweden
[2] Uppsala Univ, Dept Biochem, BMC, SE-75123 Uppsala, Sweden
[3] Medivir AB, SE-14144 Huddinge, Sweden
[4] Linkoping Univ, Dept Chem, SE-58183 Linkoping, Sweden
[5] Stockholm Univ, Arrhenius Lab, Dept Organ Chem, SE-10691 Stockholm, Sweden
[6] Uppsala Univ, BMC, Dept Mol Biol, SE-75124 Uppsala, Sweden
关键词
D O I
10.1021/jm9910371
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
tin analysis of the X-ray structure of a complex of HIV-1 protease with a linear C-2-symmetric C-terminal duplicated inhibitor guided the selection of a series of diverse target compounds. These were synthesized with the objective to identify suitable P1/P1' substituents to provide inhibitors with improved antiviral activity. Groups with various physical properties were attached to the para-positions of the P1/P1' benzyloxy groups in the parent inhibitor. A p-bromobenzyloxy compound, prepared in only three steps from commercially available starting materials, was utilized as a common precursor in all reactions. The subsequent coupling reactions were completed within a few minutes and relied on palladium catalysis and flash heating with microwave irradiation. All of the compounds synthesized exhibited good inhibitory potency in the protease assay, with K-i values ranging from 0.09 to 3.8 nM. A 30-fold improvement of the antiviral effect in cell culture, compared to the parent compound, was achieved with four of the inhibitors. The differences in K-i values were not correlated to the differences in antiviral effect, efficiency against mutant virus, or reduced potency in the presence of human serum. The poorest enzyme inhibitors in fact belong to the group with the best antiviral effect. The binding features of two structurally related inhibitors, cocrystallized with HIV-1 protease, are discussed with special emphasis on the interaction at the enzyme/water phase.
引用
收藏
页码:3835 / 3844
页数:10
相关论文
共 68 条
  • [1] Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors.: Use of L-mannaric acid as a peptidomimetic scaffold
    Alterman, M
    Björsne, M
    Mühlman, A
    Classon, B
    Kvarnström, I
    Danielson, H
    Markgren, PO
    Nillroth, U
    Unge, T
    Hallberg, A
    Samuelsson, B
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (20) : 3782 - 3792
  • [2] HIGHLY DIASTEREOSELECTIVE ALKYLATIONS OF CHIRAL AMIDE ENOLATES - NEW ROUTES TO HYDROXYETHYLENE DIPEPTIDE ISOSTERE INHIBITORS OF HIV-1 PROTEASE
    ASKIN, D
    WALLACE, MA
    VACCA, JP
    REAMER, RA
    VOLANTE, RP
    SHINKAI, I
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1992, 57 (10) : 2771 - 2773
  • [3] KOJIC AMINE - NOVEL GAMMA-AMINOBUTYRIC ACID ANALOG
    ATKINSON, JG
    GIRARD, Y
    ROKACH, J
    ROONEY, CS
    MCFARLANE, CS
    RACKHAM, A
    SHARE, NN
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1979, 22 (01) : 99 - 106
  • [4] Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor
    Backbro, K
    Lowgren, S
    Osterlund, K
    Atepo, J
    Unge, T
    Hulten, J
    Bonham, NM
    Schaal, W
    Karlen, A
    Hallberg, A
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) : 898 - 902
  • [5] ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS)
    BARRESINOUSSI, F
    CHERMANN, JC
    REY, F
    NUGEYRE, MT
    CHAMARET, S
    GRUEST, J
    DAUGUET, C
    AXLERBLIN, C
    VEZINETBRUN, F
    ROUZIOUX, C
    ROZENBAUM, W
    MONTAGNIER, L
    [J]. SCIENCE, 1983, 220 (4599) : 868 - 871
  • [6] Boehme RE, 1995, ANNU REP MED CHEM, V30, P139
  • [7] New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors:: Candidates for clinical development
    Bold, G
    Fässler, A
    Capraro, HG
    Cozens, R
    Klimkait, T
    Lazdins, J
    Mestan, J
    Poncioni, B
    Rösel, J
    Stover, D
    Tintelnot-Blomley, M
    Acemoglu, F
    Beck, W
    Boss, E
    Eschbach, M
    Hürlimann, T
    Masso, E
    Roussel, S
    Ucci-Stoll, K
    Wyss, D
    Lang, R
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3387 - 3401
  • [8] Brase S, 1998, METAL-CATALYZED CROSS-COUPLING REACTIONS, P99
  • [9] CRYSTALLOGRAPHIC R-FACTOR REFINEMENT BY MOLECULAR-DYNAMICS
    BRUNGER, AT
    KURIYAN, J
    KARPLUS, M
    [J]. SCIENCE, 1987, 235 (4787) : 458 - 460
  • [10] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58